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(20%) doses (mean ages at first Pap and first dose: 17.8 and 15.6 years). Adjusted 
incidences of any cytological abnormality (events per 100 annual person-visits) 
ranged between 11.61 with zero doses and 9.10 with three doses. Incidence rate 
ratios (IRRs) versus zero doses were 0.91 (95% CI: 0.87-0.96), 0.83 (95% CI: 0.80-
0.87), and 0.76 (95% CI: 0.74-0.79) for one, two, and three doses, respectively. For 
histology-confirmed high-grade lesions (CIN2+), IRRs versus zero doses were 0.63 
(95% CI: 0.51-0.77), 0.68 (95% CI: 0.58-0.82), and 0.47 (95% CI: 0.40-0.55) with one, 
two, and three doses, respectively. CONCLUSIONS: HPV vaccination may substan-
tially reduce the risk of cervical abnormalities in real-world settings, even when 
vaccination is incomplete. Policy and clinical efforts should focus on encouraging 
eligible girls to initiate vaccination.
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OBJECTIVES: Over 50% of oncology drugs fail in Phase III clinical trials. It remains 
imperative to better define ways of predicting whether a drug will demonstrate 
benefits prior to embarking on Phase III clinical trials. This research aims to explore 
whether Overall Response Rates (ORRs) from Phase II trials can be predictive of 
Phase III trial outcomes. METHODS: Phase III data of any Non-Small Cell Lung 
Cancer (NSCLC) and Renal Cell Carcinoma (RCC) oncologic appraised by the FDA, 
or that had failed Phase III clinical trials, since 2002 was extracted along with its 
corresponding Phase II data. RESULTS: 28 oncologics were identified with both 
Phase II and III readouts (NSCLC: 18, RCC: 10) only 12 (43%) of which met their Phase 
III trial endpoint (NSCLC: 6/18 (33%), RCC: 6/10 (60%)). Phase II ORRs varied from 
0%-61% (mean 26%) and were comparable, on average, to those seen in their cor-
responding Phase III trials (29%). 7/10 (70%) drugs with Phase II ORRs > 30% met their 
primary endpoint vs. only 5/18 (28%) with ORRs ≤ 30%. This threshold is dependent 
on whether the Phase III trial is active or placebo-controlled. For active-controlled 
Phase III trials, 3/4 (75%) met their primary endpoint with Phase II ORRs > 42% vs. 
3/12 (25%) with ORRs ≤ 42%. For placebo-controlled Phase III trials, 3/3 approved with 
Phase II ORRs > 16% versus only 3/9 with ORRs ≤ 16%. CONCLUSIONS: The magni-
tude of ORRs seen in Phase II can be correlated with later Phase III trial success in 
NSCLC and RCC. A higher Phase II ORR threshold applies where comparative benefits 
need to be shown over an active comparator in Phase III as opposed to over placebo. 
Further research can better define if such thresholds apply to other tumor types 
and whether this threshold can predict future Phase III trial failures and successes.
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OBJECTIVES: Hydrophobicity is the most important determinant of toxicity of bile 
acids (BAs) and depends on the number, position and orientation of hydroxyl groups. 
Ursodeoxycholic acid (UDCA) is a hydrophilic dihydroxy BA, which is formed by 
7β -epimerization of chenodeoxycholic acid (CDCA) in the gut by intestinal bacteria. 
Unlike the other secondary BAs, UDCA exerts antiapoptotic effects by preventing 
oxidative stress. The aim of our study was to analyze the influence of stereochemis-
try of hydroxyl groups on antiproliferative activity of BAs. METHODS: Human colon 
adenocarcinoma HT-29 cells were used to assess the cytotoxicity of CDCA and UDCA 
using colorimetric MTT assay. In order to explain obtained results of MTT assay, 12 
molecular descriptors relevant to polarity, solubility and membrane transport were 
calculated from 3D structures of CDCA and UDCA using VolSurf+ software. RESULTS: 
Studied BAs displayed distinct degrees of cytotoxicity towards HT-29 cancer cells in a 
concentration-dependent manner. Concentrations of CDCA and UDCA that inhibited 
cell growth by 50% (IC50) were 19.6 μ M and 351.9 μ M, respectively. Oxidative stress 
is considered to be the most plausible mechanism of cytotoxicity of BAs, which is 
determined mostly by their hydrophobicity. Calculated molecular descriptor that may 
explain these distinct cytotoxic effects is amphiphilic moment (A), which is defined as 
a vector pointing from the centre of hydrophobic domain to the centre of hydrophilic 
domain. The vector length (5.62 of CDCA and 4.87 of UDCA) determines the ability of 
compound to permeate a membrane. This was additionally substantiated with the 
values of CACO2, SKIN and LgBB descriptors that indicate higher Caco-2 permeability, 
skin permeability and blood-brain barrier distribution of CDCA in comparison to 
UDCA. CONCLUSIONS: More pronounced antiproliferative activity of CDCA in com-
parison to UDCA was observed. We suggest that computational methods exploring the 
physicochemical properties of molecules may help in prediction of their cytotoxicity.
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OBJECTIVES: Rigorous critical appraisal of clinical trials to assess bias and chance 
effects, which can distort trial results, can help evaluate the validity of research find-
ings. In a pre-specified integrated analysis of three phase 3 pivotal trials in patients 
with bone metastases secondary to breast cancer, prostate cancer, and other solid 
tumors or multiple myeloma (N= 5,723), denosumab was reported to be superior to 
ZA for the prevention of SREs, with statistically and clinically significant differences. 
Delfini Group performed critical appraisals of the three individual pivotal trials and 
the integrated analysis. METHODS: Published trials (Lipton et al, EJC, 2012; Stopeck 
et al, JCO, 2010; Henry et al, JCO, 2011, Fizazi et al, Lancet, 2011) were analyzed along 
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OBJECTIVES: To determine for which cancers the largest clinical advancements have 
been made, and to examine the relative health benefits offered by cancer-related 
interventions. METHODS: We used the Tufts Medical Center Cost-Effectiveness 
Analysis Registry to identify cost-utility analyses (CUAs) pertaining to cancer-related 
interventions published from 2002 through 2012. We determined the number of 
CUAs published for each cancer type, and their geographic setting. We also reported 
average incremental quality-adjusted life-year (QALY) gain for the five most studied 
cancer types, and for each cancer type the type of intervention offering largest 
health gains. RESULTS: Of the 3,244 published CUAs, 569 (17%) pertained to cancer. 
CUAs were most often set in the United States (40%), followed by United Kingdom 
(15%), Canada (9%) and Netherlands (4%). The five most studied cancers were breast 
(n= 154, 28%), colorectal (n= 62, 11%), cervical (n= 49, 9%), lung (n= 47, 8%) and prostate 
cancer (n= 46, 8%), for which interventions yielded on average, 0.32, 0.32, 0.06, 0.21, 
0.22 QALY gains, respectively. Among the five most studied cancers, the largest QALY 
gains were found for tertiary prevention interventions (mean 0.3, standard deviation 
(SD) 0.4), e.g., pharmaceuticals and surgeries; followed by secondary prevention (0.2, 
SD 0.4), e.g., diagnostic imaging. We found primary prevention interventions offered 
the smallest QALY gain (0.03, SD 0.08), e.g., immunizations. For breast and cervical 
cancer, pharmaceuticals offered the largest QALY gains, for lung and colorectal 
cancers, surgeries offered the largest QALY gains; and for prostate cancer, diagnos-
tics offered the largest QALY gains. CONCLUSIONS: We found many more CUAs for 
some cancers than for others, and that cancer-related CUAs are most often set in 
the US. The magnitude of QALY gain varied by cancer type. Pharmaceuticals offered 
the largest QALY gains for two of the five most studied cancers, but for other cancer 
types, surgeries and diagnostic imaging offered the largest QALY gains.
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OBJECTIVES: Clinical evidence supports the use of everolimus-based therapy (EVE) 
and of fulvestrant monotherapy (FUL) among postmenopausal women with hor-
mone receptor-positive human epidermal growth factor receptor-2 negative (HR+/
HER2-) metastatic breast cancer (mBC) whose disease progressed on non-steroidal 
aromatase inhibitor (NSAI). However, direct evidence was lacking on the compara-
tive effectiveness of these agents. This study compared progression-free survival 
(PFS) between EVE and FUL in a real-world setting. METHODS: This retrospective 
chart review examined postmenopausal HR+/HER2- mBC patients in community-
based oncology practices who received EVE or FUL (index therapy) for mBC as first-
line, second-line, or third- or later-lines after NSAI. PFS from index therapy initiation 
was assessed and compared using Kaplan-Meier analysis and a Cox proportional 
hazards model adjusting for index therapy line and characteristics at mBC diagnosis 
and index therapy initiation. RESULTS: A total of 192 and 156 patients received EVE 
or FUL, respectively, in a quota-based sample. EVE patients were less likely to have 
bone metastases, more likely to have visceral metastases or to have received prior 
chemotherapy for mBC, and had a shorter duration from initiation of last adjuvant 
endocrine therapy to mBC diagnosis. No significant PFS difference was observed in 
the unadjusted analysis. After adjusting for baseline characteristics, EVE patients 
had significantly longer PFS compared to FUL patients (hazard ratio [HR] = 0.71, 95% 
CI [0.51, 0.99], p = 0.045). When stratified by treatment line, second-line and third- or 
later-line EVE patients had significantly longer PFS (second-line: HR = 0.52, 95% CI 
[0.29, 0.91], p = 0.023; third- or later-lines: HR = 0.48, 95% CI [0.24, 0.93], p= 0.031) than 
FUL patients of the same treatment line. CONCLUSIONS: Among postmenopausal 
women with HR+/HER2- mBC who progressed on NSAI, the use of EVE was associ-
ated with better PFS, particularly on second-, third- and later-lines of treatment.
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OBJECTIVES: Human papillomavirus (HPV) vaccines prevent infection with the 
most cancer-causing HPV types. However, many age-eligible girls do not initiate 
or complete the three-dose regimen. There is limited information on the mag-
nitude of protection provided by partial-vaccination. We sought to empirically 
estimate the effect of HPV vaccination by dose (0, 1, 2 or 3) on cervical abnormality 
rates in a screening cohort of privately-insured U.S. girls (N= 234,829). METHODS: 
We defined a cohort within the MarketScan Commercial Claims database that 
included 9-17 year-olds in 2007 (year of vaccine introduction) who began Pap 
screening during 2008-2013. Follow-up started at subjects’ first-ever Pap and 
ended at abnormality detection or censoring. Treatment group corresponded to 
doses received before the first screening. We used inverse probability of treatment 
weighting to adjust for birth year, age/year of first Pap and first dose, plan type, 
region, zipcode-level socioeconomic factors, and claims-based sexual risk proxies. 
Weighted pooled logistic regressions estimated the effect of dose level on abnor-
mality rates. RESULTS: Subjects received zero (63%), one (8%), two (9%), or three 
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treat PTCL-not otherwise specified, angioimmunoblastic T-cell lymphoma, adult 
T-cell leukemia/lymphoma, and anaplastic large cell lymphoma patients. There 
was absence of consensus regarding standard therapeutic measures. Randomized 
controlled trials comparing different treatment approaches for PTCL are very lim-
ited due to its rarity and the heterogeneity of subtypes. METHODS: We attempt to 
collect clinical approved evidences for the efficacy and safety of pralatrexate as 
a salvage treatment for relapsed/refractory PTCL by systematic review. Searches 
based on According to National Comprehensive Cancer Network (NCCN) Guidelines 
and explicit inclusion criteria and exclusion criteria are set for literature search-
ing in PubMed, Cochrane Library and Web of Science. We evaluate primary effi-
cacy outcome (ORR and 95% CI), secondary efficacy outcomes (overall survival and 
progression-free survival duration) and safety outcomes. RESULTS: Twenty-four 
studies were initially identified for abstract screening. After further checking by 
two independent reviewers, 11 records eligible for full-text reviews. A total of 351 
relapsed/refractory PTCL patients were investigated from 11 studies. The median age 
for those treated with pralatrexate were ranged from 45 to 61.5. Before ORRs were 
compared, we adjusted the severity of diseases due to heterogeneous distribution 
of PTCL subtypes. CONCLUSIONS: Our study results indicate that pralatrexate is 
the salvage treatment of choice for the heavily pretreated patients.
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OBJECTIVES: In the era of personalized medicine, oncologists seek to tailor treatments 
for their patients based on indicators of differential response to treatment. The objec-
tive of this study was to estimate the survival benefit associated with androgen depri-
vation therapy (ADT) receipt in elderly Medicare patients newly diagnosed with Stage 
4 metastatic (S4M1) prostate cancer across patient subgroups defined by Gleason 
score and age. METHODS: We analyzed elderly men diagnosed with S4M1 prostate 
cancer between 2004-2009 in the SEER-Medicare datasets and followed through 2010 
or until loss to follow-up. An inverse probability weighted Cox proportional hazards 
model with ADT-by-age and ADT-by-Gleason score interaction terms was used to 
estimate overall survival (OS) and prostate cancer-specific survival (PCSS). RESULTS: 
Among 4,691 patients, 3,426 (73%) men received ADT within the first 6 months of 
diagnosis and 1,265 (27%) men did not receive any form of ADT (median follow-up: 17 
months). There were 3,173 total deaths in the cohort, 1,923 (61%) deaths of which were 
due to prostate cancer. Compared to the non-ADT group, ADT users had a 52%, 39%, 
59%, and 62% relative reduction in the risk of all-cause death in men aged 66-70, 71-75, 
76-80, and 80+, respectively (statistically significant; based on stratified hazard ratios 
from the Cox model). A similar trend was observed for PCSS for the age subgroups. 
Compared to the non-ADT group, ADT users had a 54% and 57% relative reduction in 
the risk of all-cause deaths and prostate cancer-specific deaths in men with Gleason 
8-10, respectively. However, the startified hazard ratios for Gleason < 8 showed no OS 
benefit (Gleason 2-6: [1.4 (0.79-2.44)] and Gleason 7: [0.88 (0.68-1.14)] or PCSS benefit 
(Gleason 2-6: [1.09 (0.53-2.20)]; Gleason 7: [1.05 (0.72-1.51)]. CONCLUSIONS: ADT was 
beneficial in terms of OS and PCSS for all age and Gleason score subgroups except 
men with Gleason score 2-6 and 7.
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OBJECTIVES: Statins may have protective effects against hepatocellular can-
cer, but no studies have focused on their clinical interactions with nucleoside 
analogues(NAs) in patients with chronic hepatitis B virus (HBV) infection. The pur-
pose of this study was to investigate the association between the use of NAs, statins 
and the risk of hepatocellular carcinoma (HCC) in HBV-infected patients. METHODS: 
A population-based matched cohort study of 91,265 HBV-infected patients enrolled 
in the Taiwan National Health Insurance Research Database since October, 2003 and 
December, 2010. 18,253 patients with NAs use were 1:4 matched as 73,012 patients 
without NAs use according to index date, age, sex, diabetes, liver cirrhosis, hyper-
tension, hyperlipidemia, biliary tract stones, chronic renal injury, alcohol related 
diseases, and COPD. Cox proportional hazards regression model for drug expo-
sures was employed to evaluate the association between NAs, statin use and HCC 
risk. RESULTS: 2841 patients were diagnosed with HCC during 262489.6 person-
years; the overall incidence rate was 1082.3 cases per 100,000 person-years or 1% per 
year. The mean follow-up time was 2.9 years. We observed a significantly lower risk 
of HCC among NAs users than among non-users (adjusted HR, 0.42; 95%CI, 0.37-0.48) 
after controlling for potential confounders, which was also found in statin users. 
In addition, we found there was a synergistic effect on NAs and statins uses. The 
adjusted HRs were 0.27 (95%CI, 0.12–0.59), 0.42 (95%CI, 0.37–0.48), and 0.62 (95%CI, 
0.47–0.84) for patients with both NAs, statin user, only NAs user, only statin user 
when comparing with non-users. CONCLUSIONS: NAs are effective in suppressing 
HBV replication and in ameliorating HBV related liver disease. Statins may have 
protective effects against hepatocellular cancer, and our study found there was a 
synergistic effect on HCC risk reduction of NAs and statins use.
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with supplementary information from study protocols, clinical study reports, and 
prescribing information. The trials were evaluated for any potential threats to study 
validity, such as selection bias, performance bias, and assessment bias, as well as the 
likelihood for chance effects instead of true effects. A detailed analysis of attrition 
(discontinuation or loss to follow up), which is a frequent issue in oncology studies, 
was also conducted to assess the presence of attrition bias. RESULTS: The integrated 
analysis and three pivotal trials were found to be of high-quality evidence and at 
low risk of bias and chance effects. Important quality features included a robust 
randomization process, high likelihood of patients remaining balanced and blinded 
throughout the study, as well as a high degree of adherence to assigned treatments. 
These and other factors, such as balance in co-interventions and in rates and reasons 
for discontinuation, make bias from attrition unlikely. CONCLUSIONS: The critical 
appraisal confirmed that the results of the integrated analysis and three pivotal trials 
were robust, with denosumab providing clinically meaningful benefit in patients with 
bone metastases from advanced cancer.
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OBJECTIVES: Clinical studies of metformin in certain cancer types have demonstrated 
decreases in incidence and improvements in therapeutic response. Preclinical evi-
dence supports multiple potential molecular pathways through which metformin 
may impart beneficial effects which impede the development and growth of head 
and neck cancer (HNC). We investigated the impact of metformin exposure following 
a diagnosis of HNC on the risk of all-cause mortality in a population-based cohort 
of Italian patients. METHODS: We used the Italian Emilia-Romagna Regional (RER) 
longitudinal healthcare database to conduct a retrospective cohort study following 
approximately 4 million adults (> = 18) from 2003 to 2011. The RER database captures 
de-identified, fully-linkable demographic, hospital discharge including ICD-9 diag-
nostic and procedure codes, outpatient pharmacy, and specialty data for all residents 
of the region. Resection status and metastases were used to stage the HNC patients 
based on surgical procedures and secondary malignancies. Cox proportional hazard 
methods were used to model the covariate-adjusted time-dependent medication 
exposure survival association to minimize potential immortal-time-bias. RESULTS: 
During the study period, we identified 7,872 patients diagnosed with HNC after which 
708 (8.99%) were exposed at some point to metformin and 3,626 (46.1%) died during 
follow-up (median = 2.98 years). Among them, after adjusting for potential confound-
ers, we found no significant association between exposure to metformin and reduced 
risk of all-cause mortality (HR= 1.03, 95% CI: 0.84 – 1.26). CONCLUSIONS: Our large 
population-based cohort study failed to find an advantage in survival outcomes for 
HNC cancer patients exposed to metformin, despite in-vitro mechanistic viability. 
Further research will be critical in clearly defining the role of metformin in HNC 
cancer survival using similar modeling approaches.
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OBJECTIVES: The aim of the study was to identify and characterize long term survival 
population of advanced non–small-cell lung cancer patients treated with immuno-
therapy. METHODS: Data from 717 patients coming from two expanded used program 
and from two randomized trials evaluating the efficacy of CIMAvaxEGF and Vaxira 
in patients with advanced NSCLC, were used. Mixture models were fitted to Overall 
Survival with one or two population components. All analyzes were made using the 
NLMIXED procedure in SAS. We used the diagnostic tools provided by this procedure 
to check the models’ good of fit properties. The characterization of the two popula-
tions based in prognostic factors was done by classification tree models using RPART 
package in R. RESULTS: Two months of overall survival (OS) benefit were showed for 
CIMAvaxEGF and for Vaxira. The optimal mixture model with the fewest number of 
parameters that adequately describes the time survival data is a mixture model with 
2 component distributions. Components represent short-term and long-term survival 
subpopulations. The proportions of the long term population increase with immu-
notherapy in 22% of patients for Vaxira and 18% for CIMAvaxEGF. The OS benefit was 
different for both subpopulation for both vaccines (vaxira: 2.08 months and 8.7 of OS 
benefit for short- and long- term survival populations respectively; CIMAvaxEGF: 1.96 
months and 14.36 months of OS benefit for short- and long- term survival populations 
respectively). The performance status and the age were essential in the classifica-
tion of the two populations. CONCLUSIONS: The results confirm that there are two 
subgroups among NLCLC patients. The separate analysis of subgroups can give more 
power to the evaluation of clinical trials. The use of mixture models in the analysis 
has implications for the design of new clinical trials. The use of classification trees 
allowed a good characterization of the two populations.
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OBJECTIVES: Pralatrexate, the first drug to gain US FDA approval for treatment 
of relapsed/refractory peripheral T-cell lymphomas (PTCL) in 2009, was aimed to 
